Cardiac involvement in beta-thalassaemia: current treatment strategies

References

• Angastiniotis M, Modell B. Global epidemiology of hemoglobin disorders. Ann N Y Acad Sci. 1998 Jun 30;850:251–269.
   PubMed Web of Science ®Google Scholar
• Camaschella C, Cappellini MD. Thalassemia intermedia. Haematologica. 1995 Feb;80(1):58–68.
   PubMed Web of Science ®Google Scholar
• Kremastinos DT, Farmakis D, Aessopos A, et al. Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circ Heart Fail. 2010 May;3(3):451–458.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998 Jun 30;850:227–231.
   PubMed Web of Science ®Google Scholar
• Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation. 1964 Nov;30:698–705.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Hatziliami A, et al. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol. 2004 Nov;73(5):359–366.
   PubMed Web of Science ®Google Scholar
• Kremastinos DT, Tsetsos GA, Tsiapras DP, et al. Heart failure in beta thalassemia: a 5-year follow-up study. Am J Med. 2001 Oct 1;111(5):349–354.
   PubMed Web of Science ®Google Scholar
• Marsella M, Borgna-Pignatti C, Melone A, et al. Cardiac iron and cardiac disease in males and females with transfusion dependent thalassemia major: a T2* magnetic resonance imaging study. Hematologica. 2011;96(4):515–520.
   PubMed Web of Science ®Google Scholar
• Pepe A, Gamberini MR, Missere M, et al. Gender differences in the development of cardiac complications: amulticentre study in a large cohort of thalassaemiamajor patients to optimize the timing of cardiac follow-up. Br J Haematol. 2018;180:879–888.
   PubMed Web of Science ®Google Scholar
• Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005 Sep 15;353(11):1135–1146.
   PubMed Web of Science ®Google Scholar
• Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci. 1998 Jun 30;850:191–201.
   PubMed Web of Science ®Google Scholar
• Wijarnpreecha K, Kumfu S, Chattipakorn SC, et al. Cardiomyopathy associated with iron overload: how does iron enter myocytes and what are the implications for pharmacological therapy? Hemoglobin. 2015;39(1):9–17.
   PubMed Web of Science ®Google Scholar
• Wood JC. Cardiac iron across different transfusion-dependent diseases. Blood Rev. 2008 Dec;22(Suppl 2):S14–21.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Porter J, et al., editors. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). 3rd ed. Nicosia (CY): Thalassaemia International Federation; 2014.
   Google Scholar
• Kremastinos DT. Heart failure in beta-thalassemia. Congest Heart Fail Greenwich Conn. 2001 Dec;7(6):312–314.
   PubMedGoogle Scholar
• Economou-Petersen E, Aessopos A, Kladi A, et al. Apolipoprotein E epsilon4 allele as a genetic risk factor for left ventricular failure in homozygous beta-thalassemia. Blood. 1998 Nov 1;92(9):3455–3459.
   PubMed Web of Science ®Google Scholar
• Dimou NL, Pantavou KG, Bagos PG. Apolipoprotein E Polymorphism and Left Ventricular Failure in Beta-Thalassemia: A Multivariate Meta-Analysis. Ann Hum Genet. 2017 Sep;81(5):213–223.
   PubMed Web of Science ®Google Scholar
• Kremastinos DT, Flevari P, Spyropoulou M, et al. Association of heart failure in homozygous beta-thalassemia with the major histocompatibility complex. Circulation. 1999 Nov 16;100(20):2074–2078.
   PubMed Web of Science ®Google Scholar
• Mokhtar GM, Sherif EM, Habeeb NM, et al. Glutathione S-transferase gene polymorphism: relation to cardiac iron overload in Egyptian patients with Beta Thalassemia Major. Hematol Am Neth. 2016 Jan;21(1):46–53.
   PubMed Web of Science ®Google Scholar
• Farmakis D, Giakoumis A, Polymeropoulos E, et al. Pathogenetic aspects of immune deficiency associated with beta-thalassemia. Med Sci Monit Int Med J Exp Clin Res. 2003 Jan;9(1):RA19–22.
   Google Scholar
• Kremastinos DT, Tiniakos G, Theodorakis GN, et al. Myocarditis in β-Thalassemia Major: A Cause of Heart Failure. Circulation. 1995 Jan 1;91(1):66–71.
   PubMed Web of Science ®Google Scholar
• Walker JM. Thalassaemia major and the heart: a toxic cardiomyopathy tamed? Heart Br Card Soc. 2013 Jun;99(12):827–834.
   PubMed Web of Science ®Google Scholar
• Russo V, Rago A, Pannone B, et al. Early electrocardiographic evaluation of atrial fibrillation risk in beta-thalassemia major patients. Int J Hematol. 2011;93:446–451.
   PubMed Web of Science ®Google Scholar
• Russo V, Rago A, Pannone B, et al. Atrial Fibrillation and Beta Thalassemia Major: thePredictive Role of the 12-lead Electrocardiogram Analysis. Indian Pacing Electrophysiol J. 3024;14(3):121–132.
   PubMedGoogle Scholar
• Detterich J, Noetzli L, Dorey F, et al. Electrocardiographic consequences of cardiac iron overload in thalassemia major. Am J Hematol. 2012 Feb;87(2):139–144.
   PubMed Web of Science ®Google Scholar
• Refaat MM, El Hage L, Steffensen AB, et al. Iron overload leading to torsades de pointes in β-thalassemia and long QT syndrome. Card Electrophysiol Clin. 2016 Mar;8(1):247–256.
   PubMedGoogle Scholar
• Russo V, Rago A, Papa AA. Electrocardiographic Presentation, Cardiac Arrhythmias, and their management in b-Thalassemia Patients Major. Ann Noninvasive Electrocardiol. 2016;21(4):335–342.
   PubMed Web of Science ®Google Scholar
• Origa R, Danjou F, Cossa S, et al. Impact of heart magnetic resonance imaging on chelationchoices, compliance with treatment and risk of heart disease inpatients with thalassemia major. Br J Haematol. 2013;163(3):400–403.
   PubMed Web of Science ®Google Scholar
• Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction ofcardiac complications in thalassemia major. J Cardiovasc Magn Reson. 2009;11(1):O2.
   PubMed Web of Science ®Google Scholar
• Pepe A, Meloni A, Rossi G, et al. Prediction of cardiac complications for thalassemia major inthe widespread cardiac magnetic resonance era: A prospectivemulticentre study by a multi‐parametric approach. Eur Heart J Cardiovasc Imaging. 2018;19:299–309.
   PubMed Web of Science ®Google Scholar
• Meloni A, Restaino G, Borsellino Z, et al. Different patterns of myocardial irondistribution by whole‐heart T2* magnetic resonance as risk markersfor heart complications in thalassemia major. Int J Cardiol. 2014;177(3):1012–1019.
   PubMed Web of Science ®Google Scholar
• Cheng CF, Lian WS. Prooxidant mechanisms in iron overloadcardiomyopathy. Biomed Res Int. 2013;2013:2013–2018.
   Web of Science ®Google Scholar
• Harada M, Van Wagoner DR, Nattel S. Role of inflammationin atrial fibrillation pathophysiology and management. Circ J. 2015;79(3):495.
   PubMed Web of Science ®Google Scholar
• Nomani H, Bayatz G, Sahbkar A, et al. Atrial fibrillation in β‐thalassemia patients with a focus on therole of iron‐overload and oxidative stress: A review. J Cell Physiol. 2018;10:1–18.
   Google Scholar
• Russo V, Papa AA, Rago A, et al. The importance of a correctmethodological approach for the arrhythmic risk evaluation in beta thalassemia major patients. Int J Cardiol. 2016;225:107–108.
   PubMed Web of Science ®Google Scholar
• Morris CR, Vichinsky EP. Pulmonary hypertension in thalassemia. Ann N Y Acad Sci. 2010 Aug;1202:205–213.
   PubMed Web of Science ®Google Scholar
• Wood JC. Cardiac complications in thalassemia major. Hemoglobin. 2009;33(Suppl 1):S81–86.
   PubMedGoogle Scholar
• Singer ST, Kuypers FA, Styles L, et al. Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Am J Hematol. 2006 Sep;81(9):670–675.
   PubMed Web of Science ®Google Scholar
• Vlahos AP, Koutsouka FP, Papamichael ND, et al. Determinants of pulmonary hypertension in patients with Beta-thalassemia major and normal ventricular function. Acta Haematol. 2012;128(2):124–129.
   PubMed Web of Science ®Google Scholar
• Gladwin MT. Role of the red blood cell in nitric oxide homeostasis and hypoxic vasodilation. Adv Exp Med Biol. 2006;588:189–205.
   PubMed Web of Science ®Google Scholar
• Hahalis G, Kremastinos DT, Terzis G, et al. Global vasomotor dysfunction and accelerated vascular aging in beta-thalassemia major. Atherosclerosis. 2008 Jun;198(2):448–457.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Loukopoulos D. Elastic tissue abnormalities resembling pseudoxanthoma elasticum in beta thalassemia and the sickling syndromes. Blood. 2002 Jan 1;99(1):30–35.
   PubMed Web of Science ®Google Scholar
• Morris CR. Vascular risk assessment in patients with sickle cell disease. Haematologica. 2011 Jan;96(1):1–5.
   PubMed Web of Science ®Google Scholar
• Koonrungsesomboon N, Chattipakorn SC, Fucharoen S, et al. Early detection of cardiac involvement in thalassemia: from bench to bedside perspective. World J Cardiol. 2013 Aug 26;5(8):270–279.
   PubMedGoogle Scholar
• Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson. 2008 Feb 25;10:12.
   PubMed Web of Science ®Google Scholar
• Kondur AK, Li T, Vaitkevicius P, et al. Quantification of Myocardial Iron Overload by Cardiovascular Magnetic Resonance Imaging T2* and Review of the Literature. Clin Cardiol. 2009 Jun 1;32(6):E54–8.
   PubMedGoogle Scholar
• Meloni A, Restaino G, Missere M, et al. Pancreatic iron overload by T2* MRI in a large cohort of well treated thalassemia major patients: can it tell us heart iron distribution and function? Am J Hematol. 2015 Sep;90(9):E189–190.
   PubMed Web of Science ®Google Scholar
• Welisch E, Norozi K, Rauch R. N-terminal pro-brain natriuretic peptide level as a screening tool for cardiac involvement in paediatric diseases of extracardiac origin. Clin Res Cardiol Off J Ger Card Soc. 2011 Sep;100(9):723–730.
   PubMed Web of Science ®Google Scholar
• Cappellini M-D, Cohen A, Eleftheriou A, et al., Guidelines for the Clinical Management of Thalassaemia [Internet] 2nd Revised. Nicosia (CY): Thalassaemia International Federation; 2008 [cited 2017 Dec 20]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK173968/
   Google Scholar
• Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004 Nov;127(3):348–355.
   PubMed Web of Science ®Google Scholar
• Chouliaras GL, Kattamis A, Berdoukas V, et al. Cardiac magnetic resonance in transfusion dependent thalassaemia: assessment of iron load and relationship to left ventricular ejection fraction. Br J Haematol. 2010 Nov;151(4):397–401.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Udelson JE, Arai AE, et al. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation. 2013 Jul 16;128(3):281–308.
   PubMed Web of Science ®Google Scholar
• Porter JB, Wood J, Olivieri N, et al. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson. 2013 May 20;15:38.
   PubMed Web of Science ®Google Scholar
• Banan M. Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? Ann Hematol. 2013 Mar;92(3):289–299.
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007 Apr 10;115(14):1876–1884.
   PubMed Web of Science ®Google Scholar
• Yang G, Liu R, Peng P, et al. How early can myocardial iron overload occur in beta thalassemia major? PloS One. 2014;9(1):e85379.
   PubMed Web of Science ®Google Scholar
• Das SK, Wang W, Zhabyeyev P, et al. Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy. Sci Rep. 2015 Dec 7;5:18132.
   PubMed Web of Science ®Google Scholar
• Jansova H, Simunek T. Cardioprotective potential of iron chelators and prochelators. Curr Med Chem. 2019;26(2):288–301.
   PubMed Web of Science ®Google Scholar
• Kumfu S, Khamseekaew J, Palee S, et al. A combination of an iron chelator with an antioxidant exerts greater efficacy on cardioprotection than monotherapy in iron-overload thalassemic mice. Free Radic Res. 2018 Jan;52(1):70–79.
   Google Scholar
• Kumfu S, Chattipakorn SC, Chattipakorn N. T-type and L-type Calcium Channel Blockers for the Treatment of Cardiac Iron Overload: an Update. J Cardiovasc Pharmacol. 2017 Nov;70(5):277–283.
   PubMed Web of Science ®Google Scholar
• Jagannath VA, Fedorowicz Z, Al Hajeri A, et al. Hematopoietic stem cell transplantation for people with ß-thalassaemia major. Cochrane Database Syst Rev. 2016 Nov 30;11:CD008708.
   PubMedGoogle Scholar
• Silvilairat S, Charoenkwan P, Saekho S, et al. Heart Rate Variability for Early Detection of Cardiac Iron Deposition in Patients with Transfusion-Dependent Thalassemia. PloS One. 2016;11(10):e0164300.
   PubMed Web of Science ®Google Scholar